Ton N M Schumacher

List of Publications by Year
in descending order

307 papers	63,621 citations	2795 94 h-index	959 238 g-index
329 all docs	329 docs citations	329 times ranked	65142 citing authors

#	Article	IF	Citations
1	Safety switches for adoptive cell therapy. Current Opinion in Immunology, 2022, 74, 190-198.	2.4	12
2	The precursors of CD8+ tissue resident memory T cells: from lymphoid organs to infected tissues. Nature Reviews Immunology, 2022, 22, 283-293.	10.6	85
3	Tertiary lymphoid structures in cancer. Science, 2022, 375, eabf9419.	6.0	303
4	QPCTL regulates macrophage and monocyte abundance and inflammatory signatures in the tumor microenvironment. OncoImmunology, 2022, 11, 2049486.	2.1	9
5	Replicative history marks transcriptional and functional disparity in the CD8+ T cell memory pool. Nature Immunology, 2022, 23, 791-801.	7.0	30
6	T cells targeted to TdT kill leukemic lymphoblasts while sparing normal lymphocytes. Nature Biotechnology, 2022, 40, 488-498.	9.4	12
7	MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial. Immuno-Oncology Technology, 2022, 15, 100089.	0.2	9
8	Labeling and tracking of immune cells in ex vivo human skin. Nature Protocols, 2021, 16, 791-811.	5.5	2
9	Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. Nature Medicine, 2021, 27, 256-263.	15.2	190
10	Formation of Tissue-Resident CD8$^+$ T-Cell Memory. Cold Spring Harbor Perspectives in Biology, 2021, 13, a038117.	2.3	11
11	Modulation of the tumor micro-environment by CD8+ T cell-derived cytokines. Current Opinion in Immunology, 2021, 69, 65-71.	2.4	14
12	Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy. Cancer Discovery, 2021, 11, 2602-2619.	7.7	90
13	Identification and characterization of a SARS-CoV-2 specific CD8+ T cell response with immunodominant features. Nature Communications, 2021, 12, 2593.	5.8	94
14	CRASH-IT Switch Enables Reversible and Dose-Dependent Control of TCR and CAR T-cell Function. Cancer Immunology Research, 2021, 9, 999-1007.	1.6	17
15	An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer. Nature Medicine, 2021, 27, 1250-1261.	15.2	159
16	HPV-16 E6/E7 DNA tattoo vaccination using genetically optimized vaccines elicit clinical and immunological responses in patients with usual vulvar intraepithelial neoplasia (uVIN): a phase I/II clinical trial. , 2021, 9, e002547.		11
17	Single-cell analysis of regions of interest (SCARI) using a photosensitive tag. Nature Chemical Biology, 2021, 17, 1139-1147.	3.9	13
18	Multimodular Optimization of Chemically Regulated T Cell Switches Demonstrates Flexible and Interchangeable Nature of Immune Cell Signaling Domains. Human Gene Therapy, 2021, 32, 1029-1043.	1.4	2

#	Article	IF	Citations
19	Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	15
20	Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8+ TÂcells. Cell Reports, 2021, 37, 110013.	2.9	38
21	Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma. Nature Communications, 2021, 12, 7348.	5.8	96
22	An atlas of intratumoral T cells. Science, 2021, 374, 1446-1447.	6.0	5
23	Tumor organoidâ€"T-cell coculture systems. Nature Protocols, 2020, 15, 15-39.	5.5	189
24	Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nature Medicine, 2020, 26, 1839-1844.	15.2	245
25	Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction. Cell, 2020, 183, 818-834.e13.	13.5	287
26	Comprehensive analysis of cutaneous and uveal melanoma liver metastases. , 2020, 8, e001501.		40
27	Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up. , 2020, 8, e000848.		79
28	A committed tissue-resident memory T cell precursor within the circulating CD8+ effector T cell pool. Journal of Experimental Medicine, 2020, 217, .	4.2	72
29	A mouse model that is immunologically tolerant to reporter and modifier proteins. Communications Biology, 2020, 3, 273.	2.0	9
30	CD29 identifies IFN-Î³â€"producing human CD8^{+}T cells with an increased cytotoxic potential. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 6686-6696.	3.3	76
31	Long-distance modulation of bystander tumor cells by CD8+ T-cell-secreted IFN-Î³. Nature Cancer, 2020, 1, 291-301.	5.7	89
32	Quorum Regulation via Nested Antagonistic Feedback Circuits Mediated by the Receptors CD28 and CTLA-4 Confers Robustness to T Cell Population Dynamics. Immunity, 2020, 52, 313-327.e7.	6.6	54
33	B cells and tertiary lymphoid structures promote immunotherapy response. Nature, 2020, 577, 549-555.	13.7	1,421
34	Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nature Medicine, 2020, 26, 566-576.	15.2	736
35	Enhanced Immunogenicity of Mitochondrial-Localized Proteins in Cancer Cells. Cancer Immunology Research, 2020, 8, 685-697.	1.6	6
36	The CD47-SIRPÎ± Immune Checkpoint. Immunity, 2020, 52, 742-752.	6.6	291

#	Article	IF	Citations
37	CD8+ T cell states in human cancer: insights from single-cell analysis. Nature Reviews Cancer, 2020, 20, 218-232.	12.8	766
38	Abstract 3412: 36-months and 18-months relapse-free survival after (neo)adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma patients - update of the OpACIN and OpACIN-neo trials. Cancer Research, 2020, 80, 3412-3412.	0.4	8
39	Abstract 3210: Strategies to improve the sensitivity and ranking ability of neoantigen prediction methods: Report on the results of the Tumor nEoantigen SeLection Alliance (TESLA). , 2020, , .		0
40	Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold. Cell, 2019, 178, 585-599.e15.	13.5	162
41	Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis. Nature, 2019, 572, 538-542.	13.7	312
42	Lineage tracing of acute myeloid leukemia reveals the impact of hypomethylating agents on chemoresistance selection. Nature Communications, 2019, 10, 4986.	5.8	24
43	Defining â€˜T cell exhaustionâ€™. Nature Reviews Immunology, 2019, 19, 665-674.	10.6	879
44	Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncology, The, 2019, 20, 948-960.	5.1	346
45	Tissue patrol by resident memory CD8+ T cells in human skin. Nature Immunology, 2019, 20, 756-764.	7.0	59
46	Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nature Medicine, 2019, 25, 920-928.	15.2	589
47	Induction of neoantigen-reactive T cells from healthy donors. Nature Protocols, 2019, 14, 1926-1943.	5.5	78
48	Broad Cytotoxic Targeting of Acute Myeloid Leukemia by Polyclonal Delta One T Cells. Cancer Immunology Research, 2019, 7, 552-558.	1.6	67
49	Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPÎ± axis and a target for cancer immunotherapy. Nature Medicine, 2019, 25, 612-619.	15.2	156
50	Radiotherapy and Cisplatin Increase Immunotherapy Efficacy by Enabling Local and Systemic Intratumoral T-cell Activity. Cancer Immunology Research, 2019, 7, 670-682.	1.6	53
51	SLFN11 can sensitize tumor cells towards IFN-Î³-mediated T cell killing. PLoS ONE, 2019, 14, e0212053.	1.1	33
52	Barcoding reveals complex clonal behavior in patient-derived xenografts of metastatic triple negative breast cancer. Nature Communications, 2019, 10, 766.	5.8	99
53	Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma. Cell, 2019, 176, 775-789.e18.	13.5	760
54	Cancer Neoantigens. Annual Review of Immunology, 2019, 37, 173-200.	9.5	384

#	Article	IF	Citations
55	Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. Nature Medicine, 2019, 25, 89-94.	15.2	413
56	Feasibility and toxicity of neoadjuvant nivolumab with or without ipilimumab prior to extensive (salvage) surgery in patients with advanced head and neck cancer (the IMCISION trial, NCT03003637).. Journal of Clinical Oncology, 2019, 37, 2575-2575.	0.8	17
57	Measuring T-cell avidity and enrichment using acoustic force-based technology.. Journal of Clinical Oncology, 2019, 37, e14010-e14010.	0.8	0
58	Abstract 5153: Measuring T-cell avidity and enrichment using an acoustic force based technology. , 2019, , .		0
59	T Cell Dysfunction in Cancer. Cancer Cell, 2018, 33, 547-562.	7.7	787
60	Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes. Cell, 2018, 172, 549-563.e16.	13.5	226
61	Regulation and Function of the PD-L1 Checkpoint. Immunity, 2018, 48, 434-452.	6.6	1,437
62	T cell receptor fingerprinting enables in-depth characterization of the interactions governing recognition of peptide–MHC complexes. Nature Biotechnology, 2018, 36, 1191-1196.	9.4	85
63	Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nature Medicine, 2018, 24, 1655-1661.	15.2	599
64	Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids. Cell, 2018, 174, 1586-1598.e12.	13.5	644
65	A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nature Medicine, 2018, 24, 994-1004.	15.2	783
66	Adaptive phase II randomized trial of nivolumab after induction treatment in triple negative breast cancer (TONIC trial): Final response data stage I and first translational data.. Journal of Clinical Oncology, 2018, 36, 1012-1012.	0.8	31
67	Immunomodulation by the combination of ipilimumab and nivolumab neoadjuvant to (salvage) surgery in advanced or recurrent head and neck carcinoma, IMCISION, an investigator-initiated phase-Ib/II trial (N16IMC, NCT03003637).. Journal of Clinical Oncology, 2018, 36, e18020-e18020.	0.8	3
68	Breadth and Dynamics of HLA-A2– and HLA-B7–Restricted CD8+ T Cell Responses against Nonstructural Viral Proteins in Acute Human Tick-Borne Encephalitis Virus Infection. ImmunoHorizons, 2018, 2, 172-184.	0.8	15
69	Abstract KN02: Keynote Lecture: T-cell recognition of human cancer. , 2018, , .		0
70	Abstract B54: Dissecting immune cell heterogeneity in human cancer by single-cell RNA-sequencing. , 2018, , .		0
71	HPV16 E7 DNA tattooing: safety, immunogenicity, and clinical response in patients with HPV-positive vulvar intraepithelial neoplasia. Cancer Immunology, Immunotherapy, 2017, 66, 1163-1173.	2.0	17
72	Guidelines for the use of flow cytometry and cell sorting in immunological studies*. European Journal of Immunology, 2017, 47, 1584-1797.	1.6	505

#	Article	IF	Citations
73	Antigen receptor repertoire profiling from RNA-seq data. Nature Biotechnology, 2017, 35, 908-911.	9.4	243
74	Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. Nature, 2017, 549, 106-110.	13.7	501
75	Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNÎ³ Signaling. Cancer Research, 2017, 77, 4562-4566.	0.4	39
76	pMHC Multiplexing Strategy to Detect High Numbers of T Cell Responses in Parallel. Methods in Molecular Biology, 2017, 1514, 93-101.	0.4	4
77	T Cells Redirected to a Minor Histocompatibility Antigen Instruct Intratumoral TNFÎ± Expression and Empower Adoptive Cell Therapy for Solid Tumors. Cancer Research, 2017, 77, 658-671.	0.4	30
78	The Human Cell Atlas. ELife, 2017, 6, .	2.8	1,547
79	Profound Immunotherapy Response in Mismatch Repair-Deficient Breast Cancer. JCO Precision Oncology, 2017, 1, 1-3.	1.5	11
80	Neoadjuvant ipilimumab + nivolumab (IPI+NIVO) in palpable stage III melanoma: Updated data from the OpACIN trial and first immunological analyses.. Journal of Clinical Oncology, 2017, 35, 9586-9586.	0.8	23
81	Abstract IA24: T cell recognition and tumor resistance in human cancer. , 2017, , .		0
82	Abstract LB-291: Identification of CMTM6 and CMTM4 as PD-L1 protein regulators. , 2017, , .		0
83	BRAF V600E Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts. Cell Reports, 2016, 16, 263-277.	2.9	61
84	Antigenâ€specific TIL therapy for melanoma: A flexible platform for personalized cancer immunotherapy. European Journal of Immunology, 2016, 46, 1351-1360.	1.6	31
85	A liquid biopsy for cancer immunotherapy. Nature Medicine, 2016, 22, 340-341.	15.2	21
86	Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science, 2016, 352, 1337-1341.	6.0	414
87	The â€œcancer immunogramâ€. Science, 2016, 352, 658-660.	6.0	655
88	Preventing tumor escape by targeting a post-proteasomal trimming independent epitope. Journal of Experimental Medicine, 2016, 213, 2333-2348.	4.2	22
89	Genomics- and Transcriptomics-Based Patient Selection for Cancer Treatment With Immune Checkpoint Inhibitors. JAMA Oncology, 2016, 2, 1490.	3.4	68
90	Editorial overview: Cancer immunology: genomics & biomarkers: Cancer immunity through the prism of genomics and proteomics. Current Opinion in Immunology, 2016, 41, ix-x.	2.4	0

#	Article	IF	Citations
91	Neoantigens encoded in the cancer genome. Current Opinion in Immunology, 2016, 41, 98-103.	2.4	65
92	Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. New England Journal of Medicine, 2016, 375, 819-829.	13.9	2,430
93	Neoantigen landscape dynamics during human melanoma–T cell interactions. Nature, 2016, 536, 91-95.	13.7	387
94	Reproducibility of Illumina platform deep sequencing errors allows accurate determination of DNA barcodes in cells. BMC Bioinformatics, 2016, 17, 151.	1.2	14
95	T Cell Fate at the Single-Cell Level. Annual Review of Immunology, 2016, 34, 65-92.	9.5	131
96	A Traceless Selection: Counter-selection System That Allows Efficient Generation of Transposon and CRISPR-modified T-cell Products. Molecular Therapy - Nucleic Acids, 2016, 5, e298.	2.3	2
97	Abstract PR11: Neo-antigen landscape dynamics during human melanoma-T cell interactions. , 2016, , .		0
98	Abstract IA04: T cell recognition and tumor resistance in human cancer. , 2016, , .		0
99	Abstract A009: Benchmarking the foreign antigen space of human malignancies. , 2016, , .		0
100	Abstract B044: Patient-specific immunotherapy through TCR gene transfer. , 2016, , .		0
101	Antigen design enhances the immunogenicity of Semliki Forest virus-based therapeutic human papillomavirus vaccines. Gene Therapy, 2015, 22, 560-567.	2.3	17
102	The Branching Point in Erythro-Myeloid Differentiation. Cell, 2015, 163, 1655-1662.	13.5	146
103	Definition of Proteasomal Peptide Splicing Rules for High-Efficiency Spliced Peptide Presentation by MHC Class I Molecules. Journal of Immunology, 2015, 195, 4085-4095.	0.4	58
104	Biomarkers in Cancer Immunotherapy. Cancer Cell, 2015, 27, 12-14.	7.7	130
105	Mismatch Repair-Deficient Cancers Are Targets for Anti-PD-1 Therapy. Cancer Cell, 2015, 28, 11-13.	7.7	69
106	Assessing T lymphocyte function and differentiation by genetically encoded reporter systems. Trends in Immunology, 2015, 36, 392-400.	2.9	20
107	Neoantigens in cancer immunotherapy. Science, 2015, 348, 69-74.	6.0	3,809
108	Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer. Science, 2015, 348, 124-128.	6.0	6,756

#	ARTICLE	IF	CITATIONS
109	Adoptive cellular therapy: A race to the finish line. Science Translational Medicine, 2015, 7, 280ps7.	5.8	320
110	Peptide Splicing in the Proteasome Creates a Novel Type of Antigen with an Isopeptide Linkage. Journal of Immunology, 2015, 195, 4075-4084.	0.4	30
111	Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor. Molecular Therapy, 2015, 23, 1541-1550.	3.7	93
112	Common myeloid progenitors are made up of distinct subpopulations that either yield erythrocytes or myeloid cells. Experimental Hematology, 2015, 43, S88.	0.2	0
113	Subtle CXCR3-Dependent Chemotaxis of CTLs within Infected Tissue Allows Efficient Target Localization. Journal of Immunology, 2015, 195, 5285-5295.	0.4	66
114	High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nature Medicine, 2015, 21, 81-85.	15.2	594
115	Functional heterogeneity of human memory CD4+ T cell clones primed by pathogens or vaccines. Science, 2015, 347, 400-406.	6.0	309
116	Bystander hyperactivation of preimmune CD8+ T cells in chronic HCV patients. ELife, 2015, 4, .	2.8	63
117	Abstract 4704: Neo-antigen enriched TIL therapy mediates superior tumor eradication in a patient-derived xenograft model of human melanoma. , 2015, , .		0
118	Segmentation of occluded hematopoietic stem cells from tracking. , 2014, 2014, 5510-3.		6
119	Altered Peptide Ligands Revisited: Vaccine Design through Chemically Modified HLA-A2–Restricted T Cell Epitopes. Journal of Immunology, 2014, 193, 4803-4813.	0.4	40
120	High sensitivity of cancer exome-based CD8 T cell neo-antigen identification. OncoImmunology, 2014, 3, e28836.	2.1	85
121	RNAi-mediated TCR Knockdown Prevents Autoimmunity in Mice Caused by Mixed TCR Dimers Following TCR Gene Transfer. Molecular Therapy, 2014, 22, 1983-1991.	3.7	59
122	Parallel In Vivo and In Vitro Melanoma RNAi Dropout Screens Reveal Synthetic Lethality between Hypoxia and DNA Damage Response Inhibition. Cell Reports, 2014, 9, 1375-1386.	2.9	34
123	TCR-Engineered T cells. , 2014, , 49-82.		0
124	TCR repertoires of intratumoral T‐cell subsets. Immunological Reviews, 2014, 257, 72-82.	2.8	59
125	Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature, 2014, 515, 577-581.	13.7	1,705
126	Manufacture of Gene-Modified Human T-Cells with a Memory Stem/Central Memory Phenotype. Human Gene Therapy Methods, 2014, 25, 277-287.	2.1	54

#	Article	IF	Citations
127	Anti–CTLA-4 therapy broadens the melanoma-reactive CD8 [+] T cell response. Science Translational Medicine, 2014, 6, 254ra128.	5.8	325
128	Determining Lineage Pathways from Cellular Barcoding Experiments. Cell Reports, 2014, 6, 617-624.	2.9	40
129	Towards error-free profiling of immune repertoires. Nature Methods, 2014, 11, 653-655.	9.0	411
130	HLA Micropolymorphisms Strongly Affect Peptide–MHC Multimer–Based Monitoring of Antigen-Specific CD8+ T Cell Responses. Journal of Immunology, 2014, 192, 641-648.	0.4	16
131	Alloreactive cytotoxic T cells provide means to decipher the immunopeptidome and reveal a plethora of tumor-associated self-epitopes. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 403-408.	3.3	40
132	Skin-resident memory CD8 [+] T cells trigger a state of tissue-wide pathogen alert. Science, 2014, 346, 101-105.	6.0	444
133	Acquired and intrinsic resistance in cancer immunotherapy. Molecular Oncology, 2014, 8, 1132-1139.	2.1	153
134	Cellular barcoding: A technical appraisal. Experimental Hematology, 2014, 42, 598-608.	0.2	65
135	Combining cellular barcoding and mathematical modeling to infer the structure of the hematopoietic pathway. Experimental Hematology, 2014, 42, S56.	0.2	0
136	Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunology, Immunotherapy, 2014, 63, 449-58.	2.0	253
137	Single cell behavior in T cell differentiation. Trends in Immunology, 2014, 35, 170-177.	2.9	28
138	Barriers to chimerism after major histocompatibility complex-mismatched stem cell transplantation: A potential role forÂheterologousÂimmunity. Experimental Hematology, 2014, 42, 753-760.	0.2	2
139	Intradermal Vaccination by DNA Tattooing. Methods in Molecular Biology, 2014, 1143, 131-140.	0.4	11
140	How T Cells Single Out Tumor Cells: "And That Has Made All the Difference"…, 2014, , 13-20.		0
141	Signatures of mutational processes in human cancer. Nature, 2013, 500, 415-421.	13.7	8,060
142	The development of standard samples with a defined number of antigen-specific T cells to harmonize T cell assays: a proof-of-principle study. Cancer Immunology, Immunotherapy, 2013, 62, 489-501.	2.0	16
143	Transposon leads to contamination of clinical pDNA vaccine. Vaccine, 2013, 31, 3274-3280.	1.7	10
144	High-throughput identification of antigen-specific TCRs by TCR gene capture. Nature Medicine, 2013, 19, 1534-1541.	15.2	166

#	Article	IF	Citations
145	Development of a Hypersensitive Periodateâ€Cleavable Amino Acid that is Methionineâ€•and Disulfideâ€Compatible and its Application in MHC Exchange Reagents for T Cell Characterisation. ChemBioChem, 2013, 14, 123-131.	1.3	22
146	Diverse and heritable lineage imprinting of early hematopoietic progenitors. Experimental Hematology, 2013, 41, S13.	0.2	1
147	Diverse and heritable lineage imprinting of early haematopoietic progenitors. Nature, 2013, 496, 229-232.	13.7	337
148	Human cancer regression antigens. Current Opinion in Immunology, 2013, 25, 284-290.	2.4	38
149	Heterogeneous Differentiation Patterns of Individual CD8$^+$ T Cells. Science, 2013, 340, 635-639.	6.0	320
150	Cancer immunotherapy. Current Opinion in Immunology, 2013, 25, 259-260.	2.4	19
151	Pairing of T‐cell receptor chains via emulsion PCR. European Journal of Immunology, 2013, 43, 2507-2515.	1.6	126
152	Blockade of TGF-Î² Signaling Greatly Enhances the Efficacy of TCR Gene Therapy of Cancer. Journal of Immunology, 2013, 191, 3232-3239.	0.4	40
153	Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma. Journal of Clinical Oncology, 2013, 31, e439-e442.	0.8	746
154	Mixed functional characteristics correlating with TCR‐ligand k_{off}‐rate of MHC‐tetramer reactive T cells within the naive T‐cell repertoire. European Journal of Immunology, 2013, 43, 3038-3050.	1.6	27
155	Discovering naturally processed antigenic determinants that confer protective T cell immunity. Journal of Clinical Investigation, 2013, 123, 1976-1987.	3.9	58
156	The cancer antigenome. EMBO Journal, 2012, 32, 194-203.	3.5	208
157	Ipilimumab-Induced Sarcoidosis in a Patient With Metastatic Melanoma Undergoing Complete Remission. Journal of Clinical Oncology, 2012, 30, e7-e10.	0.8	119
158	TIL therapy broadens the tumor-reactive CD8$^+$T cell compartment in melanoma patients. OncoImmunology, 2012, 1, 409-418.	2.1	171
159	Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma. OncoImmunology, 2012, 1, 609-617.	2.1	67
160	Dissection of T-cell Antigen Specificity in Human Melanoma. Cancer Research, 2012, 72, 1642-1650.	0.4	137
161	Nab2 regulates secondary CD8+ T-cell responses through control of TRAIL expression. Blood, 2012, 119, 798-804.	0.6	21
162	Intravital Microscopy Through an Abdominal Imaging Window Reveals a Pre-Micrometastasis Stage During Liver Metastasis. Science Translational Medicine, 2012, 4, 158ra145.	5.8	178

#	ARTICLE	IF	CITATIONS
163	Parallel detection of antigen-specific T cell responses by combinatorial encoding of MHC multimers. Nature Protocols, 2012, 7, 891-902.	5.5	131
164	Testing for HLA/peptide tetramer-binding to the T cell receptor complex on human T lymphocytes. Results in Immunology, 2012, 2, 88-96.	2.2	2
165	Tissue-resident memory CD8 $^{+}$ T cells continuously patrol skin epithelia to quickly recognize local antigen. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 19739-19744.	3.3	230
166	Behavior and Function of Tissue-Resident Memory T cells. Advances in Immunology, 2012, 114, 203-216.	1.1	44
167	Rational Design of DNA Vaccines for the Induction of Human Papillomavirus Type 16 E6- and E7-Specific Cytotoxic T-Cell Responses. Human Gene Therapy, 2012, 23, 1301-1312.	1.4	32
168	Enhanced immunogenicity of MHC class I-restricted tumor-associated altered peptide ligands. Molecular Immunology, 2012, 51, 33-34.	1.0	0
169	Discovery of low-affinity preproinsulin epitopes and detection of autoreactive CD8 T-cells using combinatorial MHC multimers. Journal of Autoimmunity, 2011, 37, 151-159.	3.0	66
170	Characterization of CD8+ T-cell response in acute and resolved hepatitis A virus infection. Journal of Hepatology, 2011, 54, 201-208.	1.8	32
171	High-Throughput Identification of Potential Minor Histocompatibility Antigens by MHC Tetramer-Based Screening: Feasibility and Limitations. PLoS ONE, 2011, 6, e22523.	1.1	36
172	The descent of memory T cells. Annals of the New York Academy of Sciences, 2011, 1217, 139-153.	1.8	35
173	Combination of targeted therapy and immunotherapy in melanoma. Cancer Immunology, Immunotherapy, 2011, 60, 1359-1371.	2.0	40
174	Preclinical development of highly effective and safe DNA vaccines directed against HPV 16 E6 and E7. International Journal of Cancer, 2011, 129, 397-406.	2.3	31
175	T-Cell Receptor Gene Therapy: Critical Parameters for Clinical Success. Journal of Investigative Dermatology, 2011, 131, 1806-1816.	0.3	38
176	An Early HIV Mutation within an HLA-B*57-Restricted T Cell Epitope Abrogates Binding to the Killer Inhibitory Receptor 3DL1. Journal of Virology, 2011, 85, 5415-5422.	1.5	57
177	Prospects and Limitations of T Cell Receptor Gene Therapy. Current Gene Therapy, 2011, 11, 276-287.	0.9	42
178	DNA Vaccines and Intradermal Vaccination by DNA Tattooing. Current Topics in Microbiology and Immunology, 2010, 351, 221-250.	0.7	26
179	MHC-based detection of antigen-specific CD8+ T cell responses. Cancer Immunology, Immunotherapy, 2010, 59, 1425-1433.	2.0	29
180	RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells. Cancer Immunology, Immunotherapy, 2010, 59, 1173-1183.	2.0	47

#	ARTICLE	IF	CITATIONS
181	Shielding the cationic charge of nanoparticle-formulated dermal DNA vaccines is essential for antigen expression and immunogenicity. Journal of Controlled Release, 2010, 141, 234-240.	4.8	67
182	Technologies for MHC class I immunoproteomics. Journal of Proteomics, 2010, 73, 1945-1953.	1.2	14
183	Lipopolysaccharide contamination in intradermal DNA vaccination: Toxic impurity or adjuvant?. International Journal of Pharmaceutics, 2010, 390, 32-36.	2.6	9
184	Apoptosis Threshold Set by Noxa and Mcl-1 after T Cell Activation Regulates Competitive Selection of High-Affinity Clones. Immunity, 2010, 32, 754-765.	6.6	78
185	Targeting B cell leukemia with highly specific allogeneic T cells with a public recognition motif. Leukemia, 2010, 24, 1901-1909.	3.3	22
186	Mapping the life histories of T cells. Nature Reviews Immunology, 2010, 10, 621-631.	10.6	50
187	One naive T cell, multiple fates in CD8+ T cell differentiation. Journal of Experimental Medicine, 2010, 207, 1235-1246.	4.2	162
188	Microbead-Assisted Retroviral Transduction for Clinical Application. Human Gene Therapy, 2010, 21, 1335-1342.	1.4	5
189	Evidence for a TCR Affinity Threshold Delimiting Maximal CD8 T Cell Function. Journal of Immunology, 2010, 184, 4936-4946.	0.4	196
190	Synthetic vehicles for DNA vaccination. Journal of Drug Targeting, 2010, 18, 1-14.	2.1	26
191	Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nature Medicine, 2010, 16, 565-570.	15.2	381
192	Development of Adoptive Cell Therapy for Cancer: A Clinical Perspective. Human Gene Therapy, 2010, 21, 665-672.	1.4	71
193	Simultaneous Detection of Circulating Autoreactive CD8+ T-Cells Specific for Different Islet Cell–Associated Epitopes Using Combinatorial MHC Multimers. Diabetes, 2010, 59, 1721-1730.	0.3	187
194	Recruitment of Antigen-Specific CD8 ⁺ T Cells in Response to Infection Is Markedly Efficient. Science, 2009, 325, 1265-1269.	6.0	133
195	αβ T Cell Receptor Transfer to γδ T Cells Generates Functional Effector Cells without Mixed TCR Dimers In Vivo. Journal of Immunology, 2009, 182, 164-170.	0.4	57
196	Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 19078-19083.	3.3	183
197	Optimization of Intradermal Vaccination by DNA Tattooing in Human Skin. Human Gene Therapy, 2009, 20, 181-189.	1.4	54
198	Preclinical development of T cell receptor gene therapy. Current Opinion in Immunology, 2009, 21, 209-214.	2.4	48

#	Article	IF	Citations
199	TCR transgenes and transgene cassettes for TCR gene therapy: status in 2008. Cancer Immunology, Immunotherapy, 2009, 58, 809-822.	2.0	58
200	Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nature Methods, 2009, 6, 520-526.	9.0	286
201	Adoptive T cell therapy of cancer. Current Opinion in Immunology, 2009, 21, 187-189.	2.4	22
202	Modular Nucleic Acid Assembled p/MHC Microarrays for Multiplexed Sorting of Antigen-Specific T Cells. Journal of the American Chemical Society, 2009, 131, 9695-9703.	6.6	84
203	Generation of Peptide MHC Class I Monomers and Multimers Through Ligand Exchange. Current Protocols in Immunology, 2009, 87, Unit 18.16.	3.6	41
204	Class I Major Histocompatibility Complexes Loaded by a Periodate Trigger. Journal of the American Chemical Society, 2009, 131, 12305-12313.	6.6	27
205	UV-Induced Ligand Exchange in MHC Class I Protein Crystals. Journal of the American Chemical Society, 2009, 131, 12298-12304.	6.6	34
206	High-Throughput T-Cell Epitope Discovery Through MHC Peptide Exchange. Methods in Molecular Biology, 2009, 524, 383-405.	0.4	52
207	The Immune System Strikes Back: Cellular Immune Responses against Indoleamine 2,3-dioxygenase. PLoS ONE, 2009, 4, e6910.	1.1	64
208	Immunotherapeutic strategies: the melanoma example. Immunotherapy, 2009, 1, 679-690.	1.0	9
209	Immunological tumor destruction in a murine melanoma model by targeted LTÎ± independent of secondary lymphoid tissue. Cancer Immunology, Immunotherapy, 2008, 57, 85-95.	2.0	54
210	Improved HIV-1 specific T-cell responses by short-interval DNA tattooing as compared to intramuscular immunization in non-human primates. Vaccine, 2008, 26, 3346-3351.	1.7	45
211	GMP production of pDERMATT for vaccination against melanoma in a phase I clinical trial. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 70, 429-438.	2.0	44
212	Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3825-3830.	3.3	150
213	Long-Term Functionality of TCR-Transduced T Cells In Vivo. Journal of Immunology, 2008, 180, 6536-6543.	0.4	22
214	TCR Gene Therapy of Spontaneous Prostate Carcinoma Requires In Vivo T Cell Activation. Journal of Immunology, 2008, 181, 2563-2571.	0.4	39
215	An Inducible Caspase 9 Safety Switch Can Halt Cell Therapy-Induced Autoimmune Disease. Journal of Immunology, 2008, 180, 6365-6373.	0.4	33
216	Requirements for Effective Antitumor Responses of TCR Transduced T Cells. Journal of Immunology, 2008, 181, 5128-5136.	0.4	52

#	Article	IF	Citations
217	Skewing the T-Cell Repertoire by Combined DNA Vaccination, Host Conditioning, and Adoptive Transfer. Cancer Research, 2008, 68, 2455-2462.	0.4	5
218	Dissecting T cell lineage relationships by cellular barcoding. Journal of Experimental Medicine, 2008, 205, 2309-2318.	4.2	107
219	Balancing between Antitumor Efficacy and Autoimmune Pathology in T-Cellâ€"Mediated Targeting of Carcinoembryonic Antigen. Cancer Research, 2008, 68, 8446-8455.	0.4	57
220	T-Cell Receptor Gene Therapy of Established Tumors in a Murine Melanoma Model. Journal of Immunotherapy, 2008, 31, 1-6.	1.2	63
221	Optimization of intradermal vaccination by DNA tattooing in human skin. Human Gene Therapy, 2008, 20, 081125111040089.	1.4	24
222	SNP-Based Genome-Wide Identification of Hematopoiesis-Restricted Minor Histocompatibility Antigens. Blood, 2008, 112, 814-814.	0.6	5
223	Functional Human Antigen-Specific T Cells Produced In Vitro Using Retroviral T Cell Receptor Transfer into Hematopoietic Progenitors. Journal of Immunology, 2007, 179, 4959-4968.	0.4	44
224	In Vivo Antigen Stability Affects DNA Vaccine Immunogenicity. Journal of Immunology, 2007, 179, 2126-2133.	0.4	37
225	Selecting highly affine and well-expressed TCRs for gene therapy of melanoma. Blood, 2007, 110, 3564-3572.	0.6	95
226	Effective graft depletion of MiHAg T-cell specificities and consequences for graft-versus-host disease. Blood, 2007, 109, 3830-3838.	0.6	11
227	Intravital imaging of fluorescent markers and FRET probes by DNA tattooing. BMC Biotechnology, 2007, 7, 2.	1.7	23
228	Vaccine leads to memory loss. Nature Medicine, 2007, 13, 248-250.	15.2	4
229	Targeting self-antigens through allogeneic TCR gene transfer. Blood, 2006, 108, 870-877.	0.6	61
230	Design and use of conditional MHC class I ligands. Nature Medicine, 2006, 12, 246-251.	15.2	304
231	Generation of peptideâ€"MHC class I complexes through UV-mediated ligand exchange. Nature Protocols, 2006, 1, 1120-1132.	5.5	293
232	Characterization of the CD8+ T cell responses directed against respiratory syncytial virus during primary and secondary infection in C57BL/6 mice. Virology, 2006, 352, 157-168.	1.1	52
233	Primary T Cell Expansion and Differentiation In Vivo Requires Antigen Presentation by B Cells. Journal of Immunology, 2006, 176, 3498-3506.	0.4	266
234	CD4 memory T cells survive and proliferate but fail to differentiate in the absence of CD40. Journal of Experimental Medicine, 2006, 203, 897-906.	4.2	43

#	ARTICLE	IF	CITATIONS
235	Generation of T Cell Help through a MHC Class I-Restricted TCR. Journal of Immunology, 2006, 177, 976-982.	0.4	39
236	Gene Transfer of MHC-Restricted Receptors. , 2005, 109, 201-214.		2
237	A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nature Medicine, 2005, 11, 899-904.	15.2	153
238	Dissection of cytotoxic and helper T cell responses. Cellular and Molecular Life Sciences, 2005, 62, 2695-2710.	2.4	14
239	MHC multimer technology: current status and future prospects. Current Opinion in Immunology, 2005, 17, 428-433.	2.4	65
240	Prospects and Limitations of T Cell Receptor Gene Therapy. Current Gene Therapy, 2005, 5, 583-593.	0.9	25
241	Epstein-Barr Virus gp42 Is Posttranslationally Modified To Produce Soluble gp42 That Mediates HLA Class II Immune Evasion. Journal of Virology, 2005, 79, 841-852.	1.5	82
242	Direct Ex Vivo Detection of HLA-DR3â€"Restricted Cytomegalovirus- and Mycobacterium tuberculosisâ€"Specific CD4+ T Cells. Human Immunology, 2005, 66, 950-961.	1.2	15
243	Antigen Bias in T Cell Cross-Priming. Science, 2004, 304, 1314-1317.	6.0	179
244	Human Telomerase Reverse Transcriptase-Transduced Human Cytotoxic T Cells Suppress the Growth of Human Melanoma in Immunodeficient Mice. Cancer Research, 2004, 64, 2153-2161.	0.4	42
245	Tumor Rejection Induced by CD70-mediated Quantitative and Qualitative Effects on Effector CD8+ T Cell Formation. Journal of Experimental Medicine, 2004, 199, 1595-1605.	4.2	136
246	Shift from Systemic to Site-Specific Memory by Tumor-Targeted IL-2. Journal of Immunology, 2004, 172, 5843-5850.	0.4	16
247	Analysis of Autoreactive CD4 T Cells in Experimental Autoimmune Encephalomyelitis after Primary and Secondary Challenge Using MHC Class II Tetramers. Journal of Immunology, 2004, 172, 2878-2884.	0.4	43
248	The Impact of Self-Tolerance on the Polyclonal CD8+ T Cell Repertoire. Journal of Immunology, 2004, 172, 2324-2331.	0.4	18
249	On the Role of Melanoma-Specific CD8+ T-Cell Immunity in Disease Progression of Advanced-Stage Melanoma Patients. Clinical Cancer Research, 2004, 10, 4754-4760.	3.2	47
250	Generating CTL by HLA transplant. Blood, 2004, 103, 4381-4382.	0.6	2
251	Tumors hijack fetal enzyme, escape killer T cells. Nature Medicine, 2003, 9, 1253-1254.	15.2	8
252	Interference with T cell receptor-HLA-DR interactions by Epstein-Barr virus gp42 results in reduced T helper cell recognition. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 11583-11588.	3.3	86

#	Article	IF	Citations
253	Single-cell perforin and granzyme expression reveals the anatomical localization of effector CD8+ T cells in influenza virus-infected mice. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 2657-2662.	3.3	150
254	CD8+ T cell tolerance and cancer immunotherapy. Journal of Immunotherapy, 2003, 26, 1-11.	1.2	55
255	Ex vivo and in situ detection of tumor-specific T-cell immunity with MHC tetramers. , 2003, , 111-130.		0
256	Can the Low-Avidity Self-Specific T Cell Repertoire Be Exploited for Tumor Rejection?. Journal of Immunology, 2002, 168, 651-660.	0.4	41
257	Specificity and affinity motifs for Grb2 SH2-ligand interactions. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 8524-8529.	3.3	63
258	Differential Kinetics of Antigen-Specific CD4+ and CD8+ T Cell Responses in the Regression of Retrovirus-Induced Sarcomas. Journal of Immunology, 2002, 169, 3191-3199.	0.4	82
259	Temporal Effects of Gamma Interferon Deficiency on the Course of Friend Retrovirus Infection in Mice. Journal of Virology, 2002, 76, 2225-2232.	1.5	37
260	Optimizing the Efficacy of Epitope-Directed DNA Vaccination. Journal of Immunology, 2002, 168, 4998-5004.	0.4	36
261	Adoptive transfer of T-cell immunity. Trends in Immunology, 2002, 23, 264-269.	2.9	32
262	Effective Postexposure Treatment of Retrovirus-Induced Disease with Immunostimulatory DNA Containing CpG Motifs. Journal of Virology, 2002, 76, 11397-11404.	1.5	49
263	In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nature Medicine, 2002, 8, 410-414.	15.2	275
264	T-cell-receptor gene therapy. Nature Reviews Immunology, 2002, 2, 512-519.	10.6	246
265	Enhanced Immunogenicity of HPV 16 E7 Fusion Proteins in DNA Vaccination. Virology, 2002, 294, 47-59.	1.1	69
266	CMV-specific CD8pos T lymphocyte differentiation in latent CMV infection. Transplantation Proceedings, 2001, 33, 1802-1803.	0.3	4
267	Differentiation of CMV-specific CD8POS T lymphocytes in primary CMV infection after renal transplantation. Transplantation Proceedings, 2001, 33, 3630.	0.3	2
268	Expression of the Serpin Serine Protease Inhibitor 6 Protects Dendritic Cells from Cytotoxic T Lymphocyteâ€"Induced Apoptosis. Journal of Experimental Medicine, 2001, 194, 657-668.	4.2	187
269	Differentiation of cytomegalovirus-specific CD8+ T cells in healthy and immunosuppressed virus carriers. Blood, 2001, 98, 754-761.	0.6	186
270	Circumventing T-cell Tolerance to Tumour Antigens. Biologicals, 2001, 29, 277-283.	0.5	7

#	ARTICLE	IF	CITATIONS
271	Immunotherapy through TCR gene transfer. Nature Immunology, 2001, 2, 957-961.	7.0	271
272	Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses. Journal of Experimental Medicine, 2001, 194, 823-832.	4.2	959
273	Low-Avidity Self-Specific T Cells Display a Pronounced Expansion Defect That Can Be Overcome by Altered Peptide Ligands. Journal of Immunology, 2001, 167, 3818-3828.	0.4	40
274	Redundancy of Direct Priming and Cross-Priming in Tumor-Specific CD8+ T Cell Responses. Journal of Immunology, 2001, 167, 3577-3584.	0.4	75
275	Tracing and characterization of the low-avidity self-specific T cell repertoire. European Journal of Immunology, 2000, 30, 1458-1468.	1.6	58
276	In situ detection of virus- and tumor-specific T-cell immunity. Nature Medicine, 2000, 6, 1056-1060.	15.2	78
277	CD27 is required for generation and long-term maintenance of T cell immunity. Nature Immunology, 2000, 1, 433-440.	7.0	662
278	Changing T cell specificity by retroviral T cell receptor display. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 14578-14583.	3.3	89
279	Junctional Biases in the Naive TCR Repertoire Control the CTL Response to an Immunodominant Determinant of HSV-1. Immunity, 2000, 12, 547-556.	6.6	49
280	Selective Expansion of Cross-Reactive Cd8+ Memory T Cells by Viral Variants. Journal of Experimental Medicine, 1999, 190, 1319-1328.	4.2	110
281	CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nature Medicine, 1999, 5, 774-779.	15.2	439
282	Accessory to murder. Nature, 1999, 398, 26-27.	13.7	10
283	Enrichment of an Antigen-Specific T Cell Response by Retrovirally Transduced Human Dendritic Cells. Cellular Immunology, 1999, 195, 10-17.	1.4	67
284	Systemic T cell expansion during localized viral infection. European Journal of Immunology, 1999, 29, 1168-1174.	1.6	76
285	Systemic T cell expansion during localized viral infection. , 1999, 29, 1168.		2
286	Bioactive and nuclease-resistant L-DNA ligand of vasopressin. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 11285-11290.	3.3	194
287	Identification of D-Peptide Ligands Through Mirror-Image Phage Display. Science, 1996, 271, 1854-1857.	6.0	330
288	Peptide length and sequence specificity of the mouse TAP1/TAP2 translocator.. Journal of Experimental Medicine, 1994, 179, 533-540.	4.2	212

#	Article	IF	Citations
289	Are MHC-bound peptides a nuisance for positive selection?. Immunity, 1994, 1, 721-723.	6.6	62
290	Transporters from H-2b, H-2d, H-2s, H-2k, and H-2g7 (NOD/Lt) haplotype translocate similar sets of peptides.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 13004-13008.	3.3	44
291	A soluble, single-chain Kd molecule produced by yeast selects a peptide repertoire indistinguishable from that of cell-surface-associated Kd. European Journal of Immunology, 1993, 23, 1776-1783.	1.6	22
292	Repertoire-Determining Role of Peptide in the Positive Selection of CD8+ T cells. Immunological Reviews, 1993, 135, 157-182.	2.8	7
293	TAP1-dependent peptide translocation in vitro is ATP dependent and peptide selective. Cell, 1993, 74, 577-584.	13.5	348
294	Peptide contributes to the specificity of positive selection of CD8+ T cells in the thymus. Cell, 1993, 73, 1041-1049.	13.5	261
295	Polymorphisms in pockets of major histocompatibility complex class I molecules influence peptide preference.. Journal of Experimental Medicine, 1993, 177, 1713-1721.	4.2	39
296	Peptide translocation by variants of the transporter associated with antigen processing. Science, 1993, 262, 2059-2063.	6.0	199
297	Synthetic peptide libraries in the determination of T cell epitopes and peptide binding specificity of class I molecules. European Journal of Immunology, 1992, 22, 1405-1412.	1.6	36
298	Preferred size of peptides that bind to H-2 Kb is sequence dependent. European Journal of Immunology, 1992, 22, 1603-1608.	1.6	43
299	A viral peptide can mimic an endogenous peptide for allorecognition of a major histocompatibility complex class I product. European Journal of Immunology, 1992, 22, 1651-1654.	1.6	38
300	Mechanisms of induction of primary virus-specific cytotoxic T lymphocyte responses. European Journal of Immunology, 1992, 22, 3013-3020.	1.6	51
301	Assembly and intracellular transport of major histocompatibility complex molecules. Current Opinion in Cell Biology, 1991, 3, 601-609.	2.6	36
302	Peptide selection by MHC class I molecules. Nature, 1991, 350, 703-706.	13.7	257
303	Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses. European Journal of Immunology, 1991, 21, 2963-2970.	1.6	95
304	Empty MHC class I molecules come out in the cold. Nature, 1990, 346, 476-480.	13.7	905
305	Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro. Cell, 1990, 62, 563-567.	13.5	415
306	Regulatory role of CD19 molecules in B-cell activation and differentiation. Cellular Immunology, 1989, 118, 368-381.	1.4	57

#	Article	IF	Citations
307	Benchmarking the Foreign Antigen Space of Human Malignancies. SSRN Electronic Journal, 0, , .	0.4	0